RIVA-VALACYCLOVIR TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)

Saadav alates:

LABORATOIRE RIVA INC.

ATC kood:

J05AB11

INN (Rahvusvaheline Nimetus):

VALACICLOVIR

Annus:

500MG

Ravimvorm:

TABLET

Koostis:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

NUCLEOSIDES AND NUCLEOTIDES

Toote kokkuvõte:

Active ingredient group (AIG) number: 0128626001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2008-10-23

Toote omadused

_RIVA-VALACYCLOVIR (Valacyclovir Tablets) _
_ _
_page 1 of 39 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RIVA-VALACYCLOVIR
Valacyclovir Tablets
Tablets, 500 mg (as valacyclovir hydrochloride), Oral
House Standard
Antiviral Agent
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control No.:
276709
Date of Initial Authorization:
OCT
23, 2008
Date of Revision:
JUL
19, 2023
_RIVA-VALACYCLOVIR (Valacyclovir Tablets) _
_ _
_page 2 of 39 _
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
..............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 5
4.5
Missed Dose
..............................................................................................................
7
5
OVERDOSAGE
................................